Outsourced transport management services for regenerative medicine products
First written in FY2018-Q3. 5 of 7 entries say "Advanced", first in FY2019-Q2. Latest entry: FY2024-Q1.
0 other companies' latest entry also says "Advanced".
- FY2024-Q1AdvancedAnnual report
「In May 2023, our consolidated subsidiary アルフレッサ株式会社 entered into a three-party basic outsourcing agreement with Kidswell Bio Corporation and Mitsubishi Logistics Corporation concerning the establishment of a high-quality, stable storage and transportation system for human deciduous tooth dental pulp stem cells being developed by Kidswell Bio Corporation as a regenerative medicine product.」
The company progressed toward establishing a storage and transport system for human deciduous tooth pulp stem cells by entering into a 3-party agreement with Kidswell Bio and Mitsubishi Logistics Corporation concerning the logistics infrastructure for regenerative medicine products. - FY2021AdvancedAnnual report
「The Group will build a nationwide distribution network using 2 regenerative medicine distribution stations in Tonomachi and Kobe and 9 storage facilities, drawing on the expertise it has developed in storing and transporting regenerative medicine products.」
The company progressed toward building a nationwide distribution network for regenerative medicine products using 2 hubs in Tonomachi and Kobe and 9 storage facilities. Additional equipment installation at 6 major logistics centers was also scheduled within FY2021. - FY2021-Q3AdvancedAnnual report
「As part of its initiatives involving regenerative medicine products, Alfresa opened the Kobe Regenerative Medicine Distribution Station in October 2020 as a new storage and transport hub for regenerative medicine products.」
The company opened the Kobe Regenerative Medicine Distribution Station as a storage and transport hub for regenerative medicine products, developing a distribution platform following the Tonomachi hub. - FY2019RestatedAnnual report
「As part of its initiatives involving regenerative medicine products, Alfresa established the Tonomachi Regenerative Medicine Distribution Station in August 2018 as a storage and transport hub for regenerative medicine products. The two companies also established a study group to examine next-generation distribution, including the joint use and efficiency improvements of logistics infrastructure for manufacturers and logistics for regenerative medicine products, for which market growth is expected.」
The company continues to report the establishment of the Tonomachi Regenerative Medicine Distribution Station and the study group with Mitsubishi Logistics Corporation as initiatives to develop logistics infrastructure for regenerative medicine products. - FY2019-Q3AdvancedAnnual report
「As part of its initiatives involving regenerative medicine products, Alfresa established the Tonomachi Regenerative Medicine Distribution Station in August 2018 on the premises of Mitsubishi Logistics Corporation (head office: Chuo-ku, Tokyo), which occupies space in the Life Innovation Center in Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa Prefecture. The center is part of a national strategic special zone involving government, industry and academia, and serves as a storage and transport hub for regenerative medicine products. The two companies also established a study group to examine next-generation distribution, including the joint use and efficiency improvements of logistics infrastructure for manufacturers and logistics for regenerative medicine products, for which market growth is expected.」
In addition to establishing the Tonomachi Regenerative Medicine Distribution Station, the company set up a study group with Mitsubishi Logistics Corporation on next-generation distribution, progressing to consideration of jointly using and improving the efficiency of logistics infrastructure for regenerative medicine products. - FY2019-Q2AdvancedAnnual report
「In August 2018, the company established the 殿町再生医療流通ステーション on the premises of Mitsubishi Logistics Corporation located within the Life Innovation Center in Tonomachi, Kawasaki, Kanagawa Prefecture. The center is part of a national strategic special zone involving industry, government and academia and serves as a storage and transportation hub for regenerative medicine products.」
In August 2018, the company established the Tonomachi Regenerative Medicine Distribution Station as a storage and transport hub for regenerative medicine products. This represented progress from outsourcing transport of clinical trial products to developing a dedicated distribution hub. - FY2018-Q3First statedAnnual report
「In December 2017, our consolidated subsidiary アルフレッサ株式会社 was commissioned by テラファーマ株式会社 to manage the transportation of investigational products for regenerative medicine being developed by テラファーマ株式会社. This was our group's first initiative involving regenerative medicine. Going forward, we will accumulate transportation experience and expertise and deliver regenerative medicine products safely and securely to patients and medical institutions nationwide that require them.」
The Group became involved in regenerative medicine for the first time and won a contract to provide transport management services for clinical trial products. It aims to build up transport experience and expertise going forward.